Package Insert: Information for the User
Alprazolam Tarbis 2 mg Tablets EFG
Read this package insert carefully before starting to take the medication, as it contains important information for you.
Alprazolam belongs to a group of medicines called benzodiazepines (anxiolytic medicines).
This medicine is used in adults for the treatment of severe, debilitating, or extremely distressing anxiety symptoms. This medicine is only for short-term use.
Warnings and precautions
To minimize the risk of dependence, the following precautions should be taken:
Alprazolam with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use another medication,
Digoxin (medication used to suppress or prevent heart rhythm alterations).
Alprazolam with food, drinks, and alcohol
During treatment, avoid alcoholic beverages. The effect of alcohol may potentiate sedation, and this may affect your alertness (see section "Driving and operating machines").
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
This medication is not recommended during pregnancy or breastfeeding, unless, in the doctor's opinion, the benefits outweigh the risks for the child.
If, by the doctor's decision, this medication is administered during a late stage of pregnancy or during delivery, the following effects may appear in the newborn: decreased body temperature (hypothermia), decreased muscle tone (hypotonia), and moderate respiratory depression.
Children born to mothers who take benzodiazepines chronically during the last period of pregnancy may develop physical dependence, and a withdrawal syndrome may be triggered in the postnatal period.
Use in children and adolescents (under 18 years)
Alprazolam is not recommended for children and adolescents under 18 years. Benzodiazepines should not be administered to children unless it is strictly necessary and prescribed by a doctor. The efficacy and safety of alprazolam have not been established in children under 18 years.
Use in elderly patients (over 65 years)
Alprazolam Tarbis may affect this group of patients more than young patients. If you belong to this group, your doctor may reduce the dose and check your response to treatment. Please follow your doctor's instructions carefully (see section "How to take Alprazolam Tarbis").
Benzodiazepines and related products should be used with caution in elderly patients, due to the risk of sedation and/or muscle weakness that may cause falls, often with serious consequences in this population.
Special patient groups
If your liver or kidneys do not function well, consult your doctor, who may advise you to use a lower dose of Alprazolam Tarbis.
If you have respiratory problems, inform your doctor.
Driving and operating machines
Alprazolam may alter your ability to drive or operate machinery; as it may cause drowsiness, decrease your attention, or decrease your reaction time. The appearance of these effects is more likely at the beginning of treatment or when increasing the dose. Do not drive or operate machines if you experience any of these effects. These effects may be potentiated if you consume alcohol at the same time.
Alprazolam contains lactose
If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication.
Alprazolam contains sodium benzoate
This medication contains0.12mg ofsodium benzoate (E-211)in each 0.25 mg tablet.
This medication contains less than 23 mg of sodium (1mmol) per tablet; it is essentially "sodium-free".
The tablet or its part will be ingested without chewing, with the help of a little liquid. Your doctor will prescribe the most suitable alprazolam presentation, according to the dose you need.
Usual doses are as follows:
- The initial dose is 0.25mg to 0.5mg of alprazolam three times a day.
-The usual dose ranges from 0.5mg to a maximum of 4 mg per day, divided into 2 or 3 doses.
In elderly patients, with chronic respiratory insufficiency, liver or kidney impairment, the initially recommended dose is 0.25mgof alprazolam, 2 or 3 times a day, with the amount of alprazolam ingested per day ranging from 0.5mg to 0.75mg in divided doses, which can be gradually increased as needed and well tolerated.
Each individual dose should not exceed the indicated limits, and the total daily dose should not either, unless your doctor indicates otherwise.
Duration and discontinuation of treatment:
The maximum durationof treatment should not bemore than 2-4 weeks. Long-term treatment is not recommended. If your doctor considers that in your case it isnecessary to prolong the treatment, they will do so for limited periods and will frequently monitor your situation.
You should never stop treatment abruptly. Your doctor will indicate the duration of treatment depending on the evolution of your disease and will explain how to gradually reduce the dose until you finish your treatment.
If you estimate that the action of this medication is too strong or too weak, inform your doctor or pharmacist.
If you take more Alprazolam than you should
Benzodiazepine overdose generally manifests by different degrees of central nervous system depression, ranging from drowsiness to coma. Symptoms include drowsiness (somnolence), speech disorders (dysarthria), coordination disturbances, confusion, lethargy (prolonged and deep sleep), decreased muscle tone (hypotonia), decreased blood pressure, respiratory depression, rarely coma, and very rarely death. Serious sequelae are rare, unless alprazolam is taken with other medications or alcohol.
In case of overdose or accidental ingestion, consult the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Alprazolam
Do not take a double dose to compensate for the missed doses.If the missed dose is recent, take your dose immediately, and if not, wait for the next dose without taking a double dose to compensate.
If you interrupt treatment with Alprazolam
Withdrawal symptoms that may occur include: headache, muscle pain, anxiety, tension, restlessness, confusion, irritability, general feeling of disgust (dysphoria), insomnia, intolerance to light, sounds, and physical contact, paresthesias and cramps in the limbs and abdomen, vomiting, sweating, tremors, depersonalization, hallucinations, and seizures. If this occurs, you should consult your doctor immediately.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Rare side effects (may affect up to 1 in 100 people):
Unknown frequency (cannot be estimated from available data):
With the use of benzodiazepines, the following may occur:
The administration of the product (even at usual doses) may lead to the development of physical dependence. Discontinuation of treatment may lead to the development of withdrawal or rebound phenomena. It may cause psychological dependence. Cases of abuse have been reported.Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 25 °C.
Store in the original packaging to protect it from light and humidity.
Do not use this medication after the expiration date that appears on the packaging after "Cad." The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Alprazolam Tarbis 2 mg tablets EFG
Appearance of the product and contents of the packaging
It is presented in scored white, oblong tablets, engraved with “APZM 2” on one face. Each package (blister) contains 30 or 50 tablets.
Other presentations:
Alprazolam Tarbis 0.25 mg tablets EFG, package with 30 tablets.
Alprazolam Tarbis 0.5 mg tablets EFG, package with 30 tablets.
Alprazolam Tarbis 1 mg tablets EFG, package with 30 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Tarbis Farma, S.L.
Gran Vía Carlos III, 94,
08028 Barcelona
Responsible for manufacturing
Dragenopharm Apotheker Püschl GmbH Co. KG
Göllstrasse 1, 84529 Tittmoning
Germany
This leaflet was last revised inJanuary 2023
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.